NYSEAMERICAN:CLDI

Calidi Biotherapeutics Q2 2026 Earnings Results & Report

Calidi Biotherapeutics logo
$0.60 -0.02 (-3.15%)
Closing price 11/16/2026 04:10 PM Eastern
Extended Trading
$0.61 +0.01 (+1.11%)
As of 11/16/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Calidi Biotherapeutics reported Q2 2026 earnings on August 13, 2026. The company reported EPS of -$2.94.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes

Calidi Biotherapeutics EPS Results

Actual EPS
-$2.94
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Calidi Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Calidi Biotherapeutics Q2 2026 Earnings FAQ

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) reported earnings of -$2.94 per share for Q2 2026. The report was announced on Thursday, August 13, 2026.

Calidi Biotherapeutics Earnings Headlines

I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
See More Calidi Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Calidi Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Calidi Biotherapeutics and other key companies, straight to your email.

About Calidi Biotherapeutics

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) is a clinical-stage biotechnology company developing cell-based therapies for cancer. Its approach uses stem cells as delivery vehicles for oncolytic viruses, which are designed to infect and destroy cancer cells and help activate the body’s immune response.

The company’s programs focus on delivering these viruses to tumors, including through its SuperNova platform, which uses engineered allogeneic stem cells. Calidi’s work remains in development, and its products are investigational rather than approved treatments.

View Calidi Biotherapeutics Profile